Emerging from the dark side : new therapeutic applications of scheduled psychoactive substances, Edward James et al., 2019

Emerging from the dark side : new therapeutic applications of scheduled psychoactive substances

Edward James, Thomas L. Robertshaw & Andrew D. Westwell

Future medicinal chemistry, February 2019

Doi : 10.4155/fmc-2018-0447


Keywords : harm reduction • healthcare • MDMA • positive psychology • psilocybin • psychoactive • psychotherapy

The discovery and development of new medicines occupies years of painstaking and expensive scientific work, with multidisciplinary teams working together in the hope of developing a new chemical entity that outperforms the current standard of care within the chosen disease setting. Once optimized in the laboratory and achieving acceptable regulatory preclinical benchmarks, years of clinical evaluation are required to persuade the regulatory authorities of a new agent’s superior efficacy in order to license a new medicine. In short, drug discovery is a high-risk and expensive business [1], with most drug candidates failing (ideally early) along the development pathway and the full cost of new drug development from ‘bench to bedside’ averaging out at an estimated $2.6 billion [2]. On the other hand, the rewards available to those companies with the global reach and resources to launch a new drug are considerable. Drug market dynamics partly explain why new branded products tend to be expensive (pitched at a price that the market can sustain), with market exclusivity protected by patent filings. It also partly explains why there is relatively little progress in areas of unmet medical need where patients and their healthcare systems simply cannot afford to pay high prices for new medicines, such as certain tropical infectious diseases.

Despite the perverse incentives toward chronic disease with large market potential, new medicine discovery as outlined above is generally regarded as the acceptable face of drug development.

In a previous editorial [3], we outlined the development of new psychoactive substances, often seen as the dark side or unacceptable face of medicinal chemistry and drug discovery. Within this market, there is little scientific rigor, and no painstaking attention to pharmaceutical quality control or indeed toxicity testing to protect the welfare of the consumer [4]. On the other hand, it is notable that among the bewildering array of new psychoactive substances consumed, many are analogs or close relatives of compounds originally discovered within pharmaceutical industry laboratories for potential treatment of CNS disorders.

In this perspective, we highlight the emergence of two drugs (Figure 1) with a bad reputation – 3,4- methylenedioxymethamphetamine (MDMA) and the prodrug psilocybin (from psilocybe mushrooms) – in the effective treatment of psychiatric disorders and their possible future availability within a healthcare context. These two selected examples, snapshots of growing activity in this field, serve to highlight the often-cited need for a grown-up and informed debate around use of scheduled (controlled) drugs.

MDMA (ecstasy; Molly) is a stimulant psychoactive drug commonly used in a recreational setting [4,5]. In most countries, MDMA is illegal as a consequence of its stimulant, empathogenic and entactogenic properties, popularity as a party drug, and occasional reported fatal overdose. The unregulated market around this illegal drug means that MDMA is sold in varying doses and often adulterated with other substances such as ephedrine and paramethoxyamphetamine [4]. Remarkably, it was estimated that around 22 million people worldwide used ecstasy in 2015, according to the UN World Drug Report [6]. Due to the numbers of users of MDMA worldwide, and comparative safety of pharmaceutical quality MDMA at low doses, there may be a future for MDMA to be sold in a healthcare setting for reducing the harms caused by recreational drugs such as black market ecstasy and new psychoactive substances [7].

MDMA has a range of effects including modulation of the serotonergic and noradrenergic systems; and induces release of the social bonding hormone oxytocin by binding to 5-HT1A receptors on hypothalamic oxytocincontaining neurons [8,9]. The effects of increased openness and empathy are reported as being a major component of the therapeutic effect of MDMA in psychotherapy and its continued recreational use [10].

MDMA has been used as an adjunct to psychotherapy since the 1970s, when it was used as an alternative to MDA (3,4-methylenedioxyamphetamine) in psychotherapy sessions after MDA was made illegal in 1970 [11]. The synthesis and studies into the psychoactive effects of MDMA were conducted by Alexander Shulgin and his wife Ann Shulgin who conducted further research into MDMA’s potential uses in psychotherapy [11].MDMA started to be used by psychotherapists as an effective aid to treatment until the drug’s scheduling by the USDrug Enforcement Agency pushed MDMA-assisted psychotherapy underground in the 1980s. Recently, Phase III clinical trials into MDMA-assisted psychotherapy have been approved after successful completion of Phase II studies for ex-military personnel, firefighters and police officers with post-traumatic stress disorder [12].

The chemical structure of psilocybin (Figure 1) is related to serotonin. Extensive research has suggested that after psilocybin has been metabolized (via dephosphorylation) to the pharmacologically active molecule psilocin, it mediates effects on the G protein-coupled 5-HT2A serotonin receptors [13,14]. Agonism of 5-HT2A receptors has effects on neuroplasticity, environmental sensitivity, learning and psychological adaptability [9].

Psilocybin has been studied for a range of conditions including alcohol [15] and tobacco [16] addiction, depression [17] and existential anxiety associated with life-threatening illness [18]. Recent studies have suggested that the mystical-type experience sometimes associated with psilocybin experiences has been correlated with therapeutic effects and a long-term increase in openness [7,18]. The results of these recent studies show psilocybin can promote enduring changes in personality traits, priorities/values and improve emotional regulation. These observations suggest that psilocybin-assisted psychotherapy could have a positive effect on a societal level and may ultimately become an important component of mainstream western medicine.

Lesser known, potentially beneficial applications of psilocybin could be described as being in the field of positive psychology. The current medical paradigm consists of attempting to bring individuals from a poor state of mental health to acceptable or good mental health. There is little provision for attempting to change a person’s mental outlook from the baseline state to excellent. Psychotherapeutic interventions typically only take place once a person has become mentally ill.We propose that psilocybin could be used as a preventative therapy in order to decrease the likelihood of at risk individuals developing poor mental health and to increase positive mental outlook. Usage of psilocybin has been associated with reduced likelihood of engaging in antisocial criminal behaviors [19], an enhanced appreciation for nature [20,21] and a decrease in sympathy for politically authoritarian perspectives [21]. In light of the benevolent changes in personality that can arise from the usage of psilocybin, it could be argued that responsible usage of psilocybin in therapeutic settings based on rigorous scientific evidence could assist in socio environmental challenges, such as climate change and interpersonal violence.